Exhibit 99.3

JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS

On June 12, 2012, pursuant to an Agreement and Plan of Merger dated as of April 26, 2012, an indirect wholly-owned subsidiary of Jazz Pharmaceuticals Public Limited Company merged with and into EUSA Pharma Inc. (“EUSA”), with EUSA continuing as the surviving corporation and as an indirect wholly owned subsidiary of Jazz Pharmaceuticals Public Limited Company (the “EUSA Acquisition”).

On January 18, 2012, the businesses of Jazz Pharmaceuticals, Inc. (“JPI”) and Azur Pharma Public Limited Company (“Azur”) were combined in a merger transaction (the “Azur Merger” and together with the EUSA Acquisition, the “Mergers”). As part of the Azur Merger, a wholly-owned subsidiary of Azur merged with and into JPI, with JPI surviving the Azur Merger as a wholly-owned subsidiary of Jazz Pharmaceuticals Public Limited Company. Prior to the Azur Merger, Azur changed its name to Jazz Pharmaceuticals Public Limited Company. The Azur Merger was accounted for as a reverse acquisition under the acquisition method of accounting for business combinations, with JPI treated as the acquiring company in the Azur Merger for accounting purposes. All references herein to “Azur” refer to Jazz Pharmaceuticals Public Limited Company prior to the completion of the Azur Merger, and all references herein to “Jazz” or the “Company” refer to Jazz Pharmaceuticals Public Limited Company as of and following the completion of the Azur Merger. Upon the consummation of the Azur Merger, the historical financial statements of JPI became the Company’s historical financial statements. Accordingly, all references herein to the historical financial statements of Jazz (or the Company) for periods prior to the Azur Merger refer to the historical financial statements of JPI.

The unaudited pro forma condensed combined balance sheet at March 31, 2012 gives effect to the EUSA Acquisition as if it had occurred on March 31, 2012. As of March 31, 2012, the acquired Azur business had been consolidated with the Company for balance sheet purposes. The unaudited pro forma condensed combined statements of operations for each of the year ended December 31, 2011 and the three months ended March 31, 2012 are presented as if the Mergers were each consummated on January 1, 2011. The pro forma financial statements presented herein are based on the historical financial statements of Jazz, Azur and EUSA using the acquisition method of accounting and applying the assumptions and adjustments described in the accompanying notes. The unaudited pro forma condensed combined statement of operations for the three months ended March 31, 2012 combined the Company’s unaudited consolidated statement of operations for the three months ended March 31, 2012 with EUSA’s unaudited consolidated statement of operations for the three months ended March 31, 2012 and Azur’s unaudited consolidated statement of operations from January 1, 2012 through the effective time of the Azur Merger on January 18, 2012.

The Jazz consolidated balance sheet and statement of operations information as of and for the three months ended March 31, 2012 was derived from its unaudited condensed consolidated financial statements included in its Form 10-Q for the three months ended March 31, 2012 (the “Jazz 10-Q”). The Jazz statement of operations information as of and for the year ended December 31, 2011 was derived from its audited consolidated financial statements included in the Annual Report on Form 10-K for the year ended December 31, 2011, filed by the Company with the SEC on behalf of and as successor to JPI (Commission File No. 001-33500) (the “Jazz 10-K”).

The EUSA consolidated balance sheet and statement of operations information as of and for the three months ended March 31, 2012 was derived from its unaudited consolidated financial statements as of March 31, 2012 included in Exhibit 99.2 to the current report on Form 8-K/A to which these unaudited pro forma condensed combined financial statements are attached as Exhibit 99.3 (the “Form 8-K/A”), and its statement of operations information for the year ended December 31, 2011 was derived from its audited consolidated financial statements for the year ended December 31, 2011 included in Exhibit 99.1 to the Form 8-K/A.

The Azur statement of operations information for the year ended December 31, 2011 was derived from its audited consolidated financial statements included in the separate Annual Report on Form 10-K for the year ended December 31, 2011 filed by the Company with the SEC (Commission File No. 333-177528) covering the last full fiscal year of Azur Pharma (the “Azur 10-K”).

The Company has not completed a full, detailed valuation analysis necessary to determine the fair values of EUSA’s identifiable assets acquired and liabilities assumed in the EUSA Acquisition. However, a preliminary valuation analysis was performed as of March 31, 2012, the date on which the EUSA Acquisition is deemed to have occurred for purposes of the unaudited pro forma condensed combined balance sheet, related to currently marketed products rights, in-process research and development, and inventories. Accordingly, the unaudited pro forma condensed combined financial statements include only preliminary estimates. The amounts of assets acquired and liabilities assumed in the acquisition accounting relating to the EUSA Acquisition were based on their respective fair values as determined at the time of closing of the EUSA Acquisition on June 12, 2012, and may differ significantly from these preliminary estimates.

The unaudited pro forma condensed combined financial statements do not give effect to the potential impact of current financial conditions, regulatory matters, operating efficiencies or other savings or expenses that may be associated with the Mergers. The unaudited pro forma condensed combined financial statements also do not include any future integration costs. The unaudited pro forma condensed combined financial statements have been prepared for illustrative purposes only and are not necessarily indicative of the financial position or results of operations in future periods or the results that actually would have been realized had JPI, EUSA and Azur been a combined company during the specified periods. The unaudited pro forma condensed

combined financial statements, including the notes thereto, should be read in conjunction with the historical audited consolidated financial statements of Jazz as of and for the year ended December 31, 2011 included in the Jazz 10-K; the historical unaudited consolidated financial statements of Jazz as of and for the three months ended March 31, 2012 included in the Jazz 10-Q; the historical audited consolidated financial statements of EUSA as of and for the year ended December 31, 2011 included in Exhibit 99.1 to the Form 8-K/A; the historical unaudited consolidated financial statements of EUSA as of and for the three months ended March 31, 2012 included in Exhibit 99.2 to the Form 8-K/A; and the historical audited consolidated financial statements of Azur as of and for the year ended December 31, 2011 included in the Azur 10-K.

F-2

Unaudited Pro Forma Condensed Combined Balance Sheet

As of March 31, 2012

(in thousands)

See accompanying notes to the unaudited pro forma condensed combined financial statements.

F-3

Unaudited Pro Forma Condensed Combined Statement of Operations

For the year ended December 31, 2011

(in thousands, except per share amounts)

See accompanying notes to the unaudited pro forma condensed combined financial statements.

F-4

Unaudited Pro Forma Condensed Combined Statement of Operations

For the three months ended March 31, 2012

(in thousands, except per share amounts)

See accompanying notes to the unaudited pro forma condensed combined financial statements.

F-5

NOTES TO UNAUDITED PRO FORMA CONDENSED

COMBINED FINANCIAL STATEMENTS

1. Basis of Presentation

On June 12, 2012, pursuant to an Agreement and Plan of Merger dated as of April 26, 2012 (the “EUSA Acquisition Agreement”), an indirect wholly-owned subsidiary of Jazz Pharmaceuticals Public Limited Company merged with and into EUSA Pharma Inc. (“EUSA”), with EUSA continuing as the surviving corporation and as an indirect wholly owned subsidiary of Jazz Pharmaceuticals Public Limited Company (the “EUSA Acquisition”).

On January 18, 2012, the businesses of Jazz Pharmaceuticals, Inc. (“JPI”) and Azur Pharma Public Limited Company (“Azur”) were combined in a merger transaction (the “Azur Merger” and together with the EUSA Acquisition, the “Mergers”). As part of the Azur Merger, a wholly-owned subsidiary of Azur merged with and into JPI, with JPI surviving the Azur Merger as a wholly-owned subsidiary of Jazz Pharmaceuticals Public Limited Company. Prior to the Azur Merger, Azur changed its name to Jazz Pharmaceuticals Public Limited Company. The Azur Merger was accounted for as a reverse acquisition under the acquisition method of accounting for business combinations, with JPI treated as the acquiring company in the Azur Merger for accounting purposes. All references herein to “Azur” refer to Jazz Pharmaceuticals Public Limited Company prior to the completion of the Azur Merger, and all references herein to “Jazz” or the “Company” refer to Jazz Pharmaceuticals Public Limited Company as of and following the completion of the Azur Merger. Upon the consummation of the Azur Merger, the historical financial statements of JPI became the Company’s historical financial statements. Accordingly, all references herein to the historical financial statements of Jazz (or the Company) for periods prior to the Azur Merger refer to the historical financial statements of JPI.

The unaudited pro forma condensed combined balance sheet at March 31, 2012 gives effect to the EUSA Acquisition as if it had occurred on March 31, 2012. As of March 31, 2012, the acquired Azur business had been consolidated with the Company for balance sheet purposes. The unaudited pro forma condensed combined statements of operations for each of the year ended December 31, 2011 and the three months ended March 31, 2012 are presented as if the Mergers were each consummated on January 1, 2011. The unaudited pro forma condensed combined financial information was prepared using the acquisition method of accounting, based on the historical financial statements of Jazz, EUSA and Azur. Certain reclassifications have been made to the historical financial statements of EUSA to conform to the financial statement presentation adopted by the combined company. All such reclassifications have been included in Pro Forma Adjustments in the Unaudited Pro Forma Condensed Combined Balance Sheet and Unaudited Pro Forma Condensed Combined Statements of Operations.

EUSA Acquisition

At the closing of the EUSA Acquisition, the Company made a cash payment of $678.4 million. The Company also agreed to make an additional contingent payment of $50.0 million in cash if Erwinaze, EUSA’s lead product, achieves U.S. net sales of $124.5 million in 2013. At closing, $50.0 million of the amount paid of the EUSA Acquisition was deposited in an escrow account, to be held for 12 months as partial security for the Company’s indemnification rights under the EUSA Acquisition Agreement. $25.0 million of the potential contingent payment, if payable, would be subject to reduction for indemnification claims, if any, that are not fully satisfied by the funds in the escrow account. The total estimated acquisition consideration for the purchase of EUSA was determined as of June 12, 2012, the date on which the EUSA Acquisition occurred. The total estimated acquisition consideration for the EUSA Acquisition is comprised of cash and the fair value of the $50.0 million contingent consideration exchanged in the EUSA Acquisition. The fair value of the contingent consideration was established by adjusting for the probability of achieving the net sales milestone described above and discounting it to its present value. Total estimated acquisition consideration is as follows (in thousands):

Under the acquisition method of accounting, identifiable assets and liabilities of EUSA, including identifiable intangible assets, were recorded based on their estimated fair values as of the effective time of the EUSA Acquisition. Goodwill is calculated as the difference between the estimated acquisition consideration and fair values of identifiable net assets acquired.

The estimated acquisition consideration and the preliminary allocation of the estimated acquisition consideration are, in part, based upon a preliminary management valuation, as described below, and the Company’s estimates and assumptions which are subject to change.

Tangible assets and liabilities: Tangible assets and liabilities were valued at their respective carrying amounts, except for adjustments to inventories. Management believes that these amounts approximate their current fair values as of the deemed acquisition date of March 31, 2012.

Inventories: Inventories acquired include raw materials, work-in-process and finished goods. The fair value of finished goods has been determined based on the estimated selling price, net of selling costs and a margin on the selling costs. The fair value of work-in-process has been determined based on the estimated selling price, net of selling costs and costs to complete and a margin on the selling costs. The fair value of raw materials has been estimated to equal their replacement cost.

Identifiable intangible assets and liabilities: Identifiable intangible assets and liabilities acquired include currently marketed products and in-process research and development. The fair value of intangible assets is based on management’s preliminary valuation as of the deemed acquisition date of March 31, 2012. Estimated useful lives (where relevant for the purposes of these unaudited pro forma financial statements) are based on the time periods during which the intangibles are expected to result in incremental cash flows.

F-6

Goodwill: Goodwill represents the excess of the preliminary acquisition consideration over the estimated fair values of net assets acquired. Goodwill will not be amortized but will be tested for impairment at least annually or whenever certain indicators of impairment are present. In the future, if it is determined that goodwill is impaired, an impairment charge would be recorded at that time.

Deferred tax assets and liabilities: Deferred tax assets and liabilities arise from acquisition accounting adjustments where book values of certain assets and liabilities differ from their tax bases. Deferred tax assets and liabilities are recorded at the currently enacted rates which will be in effect at the time when the temporary differences are expected to reverse in the country where the underlying assets and liabilities are located.

Pre-acquisition contingencies: The Company has not currently identified any pre-acquisition contingencies where a liability is probable and the amount of the liability can be reasonably estimated. If information becomes available to management prior to the end of the measurement period (no longer than 12 months after the closing of the EUSA Acquisition), which would indicate that a liability is probable and the amount can be reasonably estimated, such items will be reflected in the acquisition accounting.

The preliminary determination of the fair value of the acquired net assets, assuming the EUSA Acquisition had closed on March 31, 2012, is as follows (in thousands):

F-7

The final determination of the fair value of the identifiable net assets acquired will be based on EUSA’s assets acquired and liabilities assumed as of the effective time of the EUSA Acquisition on June 12, 2012.

Azur Merger

Under the acquisition method of accounting, assets and liabilities of Azur were recorded at their respective fair values and added to those of JPI including an amount for goodwill representing the difference between the acquisition consideration and the fair value of the identifiable net assets. For additional information regarding the Azur Merger see Form 8-K filed by Jazz on February 28, 2012 with the SEC (Commission File No. 001-33500).

2. Pro Forma Adjustments

Pro forma adjustments are necessary to reflect the estimated acquisition consideration and to adjust amounts related to the tangible and intangible assets and liabilities of EUSA to a preliminary estimate of their fair values, and to reflect the impact on the statements of operations of the Mergers as if the companies had been combined during the periods presented therein. The pro forma adjustments included in the unaudited pro forma condensed combined financial statements are as follows:

The new debt incurred by Jazz in June 2012 to partially fund the EUSA Acquisition is comprised of a six-year term loan facility of $475.0 million. Borrowings under the term loan bear interest, at Jazz’s option, at a rate equal to either the LIBOR rate, plus an applicable margin of 4.25% per annum (subject to a 1.0% LIBOR floor), or the prime lending rate, plus an applicable margin equal to 3.25% per annum (subject to a 2.0% prime rate floor). Currently LIBOR rates are below the floor of 1% and therefore an increase in interest rates would only impact Jazz’s net interest expense to the extent it exceeds the floor of 1%. Based on variable rate debt levels of $475.0 million as of June 30, 2012, a 1/8 of a percent (0.125%) change in interest rates, above the LIBOR floor, would impact Jazz’s annual pro forma interest expense by $0.6 million.

F-8

3. Non-recurring Transaction Costs

Jazz, EUSA and Azur have incurred, and Jazz will continue to incur, certain non-recurring transaction expenses. Non-recurring transaction expenses incurred were $14.2 million and $15.6 million during the year ended December 31, 2011 and for the three months ended March 31, 2012, respectively, and are reflected as an adjustment to reduce selling, general and administrative expenses in the pro forma condensed combined statements of operations as they are non-recurring and directly attributable to the Mergers. The pro forma condensed combined balance sheet as of March 31, 2012 includes an adjustment of $8.9 million to accrued liabilities for transaction expenses incurred by Jazz subsequent to March 31, 2012 (see Note 2, Pro Forma Adjustments above). These transaction expenses are not reflected in the pro forma condensed combined statement of operations for the three months ended March 31, 2012, as they are not expected to have a continuing impact on operations. Estimated transaction expenses of EUSA which were contingent on consummation of the EUSA Acquisition or had not been incurred as of March 31, 2012 totaled $8.6 million and were paid by Jazz on behalf of the former EUSA shareholders upon closing. Accordingly, these transaction expenses have not been included in assumed liabilities as of March 31, 2012.

F-9